These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3140733)

  • 1. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
    Yasumura T; Oka T; Honjo H; Okada H
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
    Ravdin PM; Fritz NF; Tormey DC; Jordan VC
    Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
    Jordan VC; Fritz NF; Tormey DC
    Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
    Reh A; Oktem O; Oktay K
    Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
    Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
    Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
    Rose DP; Davis TE
    Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
    Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.
    Manni A; Pearson OH
    Cancer Treat Rep; 1980; 64(6-7):779-85. PubMed ID: 6775808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian function and childbearing issues in breast cancer survivors.
    Gadducci A; Cosio S; Genazzani AR
    Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma.
    Shamberger RC; Sherins RJ; Ziegler JL; Glatstein E; Rosenberg SA
    J Natl Cancer Inst; 1981 Dec; 67(6):1213-8. PubMed ID: 6796744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
    Bianco AR; De Placido S; Pagliarulo C; Fasano S; D'Istria M; De Sio L; Ricciardi I; Delrio G
    Chemioterapia; 1985 Jun; 4(3):252-5. PubMed ID: 3839720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cyst formation in patients using tamoxifen for breast cancer.
    Metindir J; Aslan S; Bilir G
    Jpn J Clin Oncol; 2005 Oct; 35(10):607-11. PubMed ID: 16254040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of chemotherapy to ovary function in ovarian malignancy patients undergoing conservative surgery].
    Sun ZY; Shen K; Lang JH; Huang HF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):431-3. PubMed ID: 12974089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.